Macrogenics Inc (NASDAQ: MGNX) on Tuesday, plunged -4.02% from the previous trading day, before settling in for the closing price of $5.47. Within the past 52 weeks, MGNX’s price has moved between $3.14 and $21.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 15.77%. The company achieved an average annual earnings per share of -1569.43%. With a float of $58.46 million, this company’s outstanding shares have now reached $62.07 million.
Let’s determine the extent of company efficiency that accounts for 339 employees.
Macrogenics Inc (MGNX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Macrogenics Inc is 6.66%, while institutional ownership is 104.76%. The most recent insider transaction that took place on Apr 04 ’24, was worth 799,148. In this transaction Senior VP and General Counsel of this company sold 51,395 shares at a rate of $15.55, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 06 ’24, when Company’s Senior VP and General Counsel sold 19,625 for $21.50, making the entire transaction worth $421,938. This insider now owns 8,895 shares in total.
Macrogenics Inc (MGNX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -1569.43% per share during the next fiscal year.
Macrogenics Inc (NASDAQ: MGNX) Trading Performance Indicators
Macrogenics Inc (MGNX) is currently performing well based on its current performance indicators. A quick ratio of 3.61 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.66 in the next quarter and is forecasted to reach -1.90 in one year’s time.
Technical Analysis of Macrogenics Inc (MGNX)
Looking closely at Macrogenics Inc (NASDAQ: MGNX), its last 5-days average volume was 0.68 million, which is a drop from its year-to-date volume of 1.83 million. As of the previous 9 days, the stock’s Stochastic %D was 63.51%. Additionally, its Average True Range was 0.37.
During the past 100 days, Macrogenics Inc’s (MGNX) raw stochastic average was set at 11.31%, which indicates a significant decrease from 65.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.67% in the past 14 days, which was lower than the 254.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.60, while its 200-day Moving Average is $10.17. However, in the short run, Macrogenics Inc’s stock first resistance to watch stands at $5.54. Second resistance stands at $5.82. The third major resistance level sits at $5.98. If the price goes on to break the first support level at $5.10, it is likely to go to the next support level at $4.94. Should the price break the second support level, the third support level stands at $4.66.
Macrogenics Inc (NASDAQ: MGNX) Key Stats
Market capitalization of the company is 328.81 million based on 62,633K outstanding shares. Right now, sales total 58,750 K and income totals -9,060 K. The company made 9,100 K in profit during its latest quarter, and -52,190 K in sales during its previous quarter.
